Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AYTU BIOPHARMA, INCAYTU · Entity 7560 | Director · Chief Executive Officer | July 28, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AYTU BIOPHARMA, INC
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 237,203 |
Reported balance
After 2026-07-28 transaction · row 1
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 30,000 · Balance 237,203 F1: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ZYNEX INC
Report date March 26, 2026 · Filed March 27, 2026
Section 16 reporting ended · disclosed 2026-03-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (Restricted Stock Award)SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-03-26 transaction · row 1
1 source rowRow 1 · 2026-03-26 · Disposition to issuer · Disposed 12,499 · Balance 0 F1: Pursuant to the Issuer's Third Amended Combined Disclosure Statement and Joint Chapter 11 Plan of Reorganization of Zynex, Inc. and Its Affiliated Debtors Pursuant to Chapter 11 of the Bankruptcy Code (the "Plan") which was confirmed by the United States Bankruptcy Court for the Southern District of Texas on March 19, 2026 and became effective on March 26, 2026, all outstanding shares of the Issuer's common stock (including shares of common stock issuable under equity awards granted under the Issuer's equity incentive plans) and all other options, warrants and other rights with respect thereto, have been cancelled for no consideration and of no further force and effect with no recovery under the Plan. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-03-26 transaction · row 2
1 source rowRow 2 · 2026-03-26 · Disposition to issuer · Disposed 89,501 · Balance 0 F1: Pursuant to the Issuer's Third Amended Combined Disclosure Statement and Joint Chapter 11 Plan of Reorganization of Zynex, Inc. and Its Affiliated Debtors Pursuant to Chapter 11 of the Bankruptcy Code (the "Plan") which was confirmed by the United States Bankruptcy Court for the Southern District of Texas on March 19, 2026 and became effective on March 26, 2026, all outstanding shares of the Issuer's common stock (including shares of common stock issuable under equity awards granted under the Issuer's equity incentive plans) and all other options, warrants and other rights with respect thereto, have been cancelled for no consideration and of no further force and effect with no recovery under the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's Third Amended Combined Disclosure Statement and Joint Chapter 11 Plan of Reorganization of Zynex, Inc. and Its Affiliated Debtors Pursuant to Chapter 11 of the Bankruptcy Code (the "Plan") which was confirmed by the United States Bankruptcy Court for the Southern District of Texas on March 19, 2026 and became effective on March 26, 2026, all outstanding shares of the Issuer's common stock (including shares of common stock issuable under equity awards granted under the Issuer's equity incentive plans) and all other options, warrants and other rights with respect thereto, have been cancelled for no consideration and of no further force and effect with no recovery under the Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 30, 2026 20:34 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-025083 · rdgdoc.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,203 F1 · shares: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 18:00 UTC | ZYNEX INC ZYXI · Entity 55698 | Disposition to issuerCommon Stock | 89,501 | $0.00 | $0.00 |
DisclosureSEC source: 0001566240-26-000002 · form4-03272026_100355.xml · nonDerivative · entry 2 Disbrow Joshua R. · CIK 0001566240 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Issuer's Third Amended Combined Disclosure Statement and Joint Chapter 11 Plan of Reorganization of Zynex, Inc. and Its Affiliated Debtors Pursuant to Chapter 11 of the Bankruptcy Code (the "Plan") which was confirmed by the United States Bankruptcy Court for the Southern District of Texas on March 19, 2026 and became effective on March 26, 2026, all outstanding shares of the Issuer's common stock (including shares of common stock issuable under equity awards granted under the Issuer's equity incentive plans) and all other options, warrants and other rights with respect thereto, have been cancelled for no consideration and of no further force and effect with no recovery under the Plan. Read SEC document |
| March 26, 2026 Filed Mar 27, 2026 18:00 UTC | ZYNEX INC ZYXI · Entity 55698 | Disposition to issuerCommon Stock (Restricted Stock Award) | 12,499 | $0.00 | $0.00 |
DisclosureSEC source: 0001566240-26-000002 · form4-03272026_100355.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Issuer's Third Amended Combined Disclosure Statement and Joint Chapter 11 Plan of Reorganization of Zynex, Inc. and Its Affiliated Debtors Pursuant to Chapter 11 of the Bankruptcy Code (the "Plan") which was confirmed by the United States Bankruptcy Court for the Southern District of Texas on March 19, 2026 and became effective on March 26, 2026, all outstanding shares of the Issuer's common stock (including shares of common stock issuable under equity awards granted under the Issuer's equity incentive plans) and all other options, warrants and other rights with respect thereto, have been cancelled for no consideration and of no further force and effect with no recovery under the Plan. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:11 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-030642 · rdgdoc.xml · nonDerivative · entry 2 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,203 F2 · shares: Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:11 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 31,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-030642 · rdgdoc.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,703 F1 · shares: The reporting person was granted fully vested restricted stock in lieu of cash in satisfaction of their annual bonus. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 19:04 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Stock | 66,666 | $1.50 | $99,999.00 |
DisclosureSEC source: 0001437749-25-019956 · rdgdoc.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,257 F1 · shares: Purchased pursuant to the Issuer's registered offering more particularly described on the Registration Statement on Form S-1, as amended, filed by the Issuer on June 2, 2025. Read SEC document |
| May 15, 2025 Filed May 16, 2025 18:00 UTC | ZYNEX INC ZYXI · Entity 55698 | GrantCommon Stock (Restricted Stock Award) | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013482 · form4-05162025_060505.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 F1 · shares: Represents a restricted stock award issued pursuant to the Issuer's 2017 Stock Incentive Plan (the "Plan") pursuant to which the 10,000 shares vest equally, on a quarterly basis, over a period of three years beginning one quarter from the grant date. F2 · balance_after: Represents restricted stock awards under the Plan, which have not vested. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 18:35 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Stock | 15,000 | $1.30 | $19,500.00 |
DisclosureSEC source: 0001437749-25-005873 · rdgdoc.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,591 F1 · shares: On February 28, 2025, Joshua R. Disbrow, purchased a total of 15,000 shares of common stock in multiple open market transaction at prices per share ranging from $1.29 to $1.30, with a weighted average price of approximately $1.30 per share. Mr. Disbrow undertakes to provide to AYTU BIOPHARMA, INC., any security holder of AYTU BIOPHARMA, INC., or the staff of the United States Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F1 · price: On February 28, 2025, Joshua R. Disbrow, purchased a total of 15,000 shares of common stock in multiple open market transaction at prices per share ranging from $1.29 to $1.30, with a weighted average price of approximately $1.30 per share. Mr. Disbrow undertakes to provide to AYTU BIOPHARMA, INC., any security holder of AYTU BIOPHARMA, INC., or the staff of the United States Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 06, 2024 Filed Nov 9, 2024 00:55 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0000912282-24-000758 · form4.xml · derivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Shares · 38,000 shares Expires 2034-11-06 F1 · derivative.exercise_date: The options vest as follows: 1/3 on November 6, 2025, with the remaining options vesting in 24 equal monthly installments beginning December 6, 2025. Read SEC document |
| July 29, 2024 Filed Jul 30, 2024 18:25 UTC | ZYNEX INC ZYXI · Entity 55698 | PurchaseCommon Stock | 7,000 | $8.32 | $58,233.00 |
DisclosureSEC source: 0001415889-24-020376 · form4-07302024_100722.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 F1 · shares: On July 29, 2024, Joshua Disbrow, purchased 7,000 shares of common stock in an open market transaction at a price per share equal to $8.319, increasing Mr. Disbrow's beneficially owned shares to 72,000 shares. Read SEC document |
| May 16, 2024 Filed May 17, 2024 17:00 UTC | ZYNEX INC ZYXI · Entity 55698 | GrantCommon Stock (Restricted Stock Award) | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-013558 · form4-05172024_050503.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,587 F1 · shares: Represents a restricted stock award issued pursuant to the Issuer's 2017 Stock Incentive Plan (the "Plan") pursuant to which the 10,000 shares vest equally, on a quarterly basis, over a period of three years beginning one quarter from the grant date. F2 · balance_after: Represents restricted stock awards under the Plan, which have not vested. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 23:34 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0000912282-23-000299 · form4.xml · derivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 35,000 shares Expires 2033-08-12 F1 · derivative.exercise_date: The options vest as follows: 1/3 on August 11, 2024, with the remaining options vesting in 24 equal monthly installments beginning September 11, 2024. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 17:30 UTC | ZYNEX INC ZYXI · Entity 55698 | GrantCommon Stock (Restricted Stock Award) | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-072360 · tm2319010-2_4seq1.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,171 F1 · shares: Represents a restricted stock award issued pursuant to the Issuer's 2017 Stock Incentive Plan (the "Plan") pursuant to which the 10,000 shares vest equally, on a quarterly basis, over a period of three years beginning one quarter from the grant date. F2 · balance_after: Represents restricted stock awards under the Plan, which have not vested. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 17:52 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Shares | 14,000 | $1.86 | $26,079.20 |
DisclosureSEC source: 0000912282-23-000133 · form4.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,591 F1 · price: The purchase price reported in Column 4 above is an average weighted price. These shares were purchased in multiple transactions at prices ranging from $1.79 to $1.87, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · balance_after: Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023. Read SEC document |
| December 20, 2022 Filed Dec 23, 2022 22:27 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-021999 · doc1.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151,877 F1 · shares: On December 21, 2022, the reporting person and the Issuer determined to rescind 80,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer. F1 · price: On December 21, 2022, the reporting person and the Issuer determined to rescind 80,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 14:17 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Stock | 112,371 | $0.22 | $25,047.50 |
DisclosureSEC source: 0001567619-22-021900 · doc1.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,231,877 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.213 to $0.23, inclusive. The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 14:30 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Shares | 222,000 | $0.24 | $52,614.00 |
DisclosureSEC source: 0001654954-22-015599 · section16.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,119,506 Read SEC document |
| November 18, 2022 Filed Nov 28, 2022 21:30 UTC Amendment | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Shares | 222,000 | $0.24 | $52,614.00 |
DisclosureSEC source: 0001567619-22-020922 · doc1.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,119,506 Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 17:19 UTC | ZYNEX INC ZYXI · Entity 55698 | GrantCommon Stock (Restricted Stock Award) | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-067713 · tm2217566-2_4seq1.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,208 F1 · shares: Represents a restricted stock award issued pursuant to the Issuer's 2017 Stock Incentive Plan (the "Plan") pursuant to which the 10,000 shares vest equally, on a quarterly basis, over a period of three years beginning one quarter from the grant date. F2 · balance_after: Represents restricted stock awards under the Plan, which have not vested. Read SEC document |
| July 16, 2021 Filed Jul 19, 2021 18:55 UTC | ZYNEX INC ZYXI · Entity 55698 | GrantCommon Stock (Restricted Stock Award) | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-093611 · tm2122577-3_4seq1.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,751 F1 · shares: Represents a restricted stock award issued pursuant to the Issuer's 2017 Stock Incentive Plan (the "Plan") pursuant to which the 10,000 shares vest equally, on a quarterly basis, over a period of three years beginning one quarter from the grant date. F2 · balance_after: Represents restricted stock awards under the Plan, which have not vested. Read SEC document |
| April 16, 2021 Filed Apr 16, 2021 20:49 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 800,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-008228 · doc1.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 897,506 F1 · shares: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). (4) At the Compensation Committee's discretion based on the Company achieving certain revenue milestones and the successful integration of future acquisitions. The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer. F1 · price: Grant of restricted shares. The restricted shares have the following accelerated vesting conditions: (1) The consummation of a Sale Event. (2) The closing price of the Company's stock price is equal or greater than forty dollars per share ($40) for two consecutive trading days. (3) The Grantee's service with the Company or a Related Entity is terminated by the Company without Cause (as defined below). (4) At the Compensation Committee's discretion based on the Company achieving certain revenue milestones and the successful integration of future acquisitions. The restricted shares vest as follows, and have no voting or dispositive rights until vested: 1/3 on April 16, 2022, and 1/12 on the first day of each quarter thereafter, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continuing employment with the Issuer. Read SEC document |
| July 29, 2020 Filed Jul 30, 2020 21:34 UTC | ZYNEX INC ZYXI · Entity 55698 | GrantCommon Stock (Restricted Stock Award) | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-088595 · tm2026157d2_4.xml · nonDerivative · entry 2 Disbrow Joshua R. · CIK 0001566240 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F3 · shares: Represents a restricted stock award issued pursuant to the Issuer's 2017 Stock Incentive Plan (the "Plan") pursuant to which the 10,000 shares vest equally, on a quarterly basis, over a period of three years beginning one quarter from the grant date. F2 · balance_after: Represents restricted stock awards under the Plan, which have not vested. Read SEC document |
| July 29, 2020 Filed Jul 30, 2020 21:34 UTC | ZYNEX INC ZYXI · Entity 55698 | GrantCommon Stock (Restricted Stock Award) | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-088595 · tm2026157d2_4.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents a restricted stock award issued pursuant to the Issuer's 2017 Stock Incentive Plan (the "Plan") pursuant to which the 10,000 shares vest equally, on a quarterly basis, over a period of two years beginning one quarter from the grant date. F2 · balance_after: Represents restricted stock awards under the Plan, which have not vested. Read SEC document |
| June 08, 2020 Filed Jun 12, 2020 21:44 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 100,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001654954-20-006583 · section16.xml · derivative · entry 2 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,275 Underlying: Common Stock · 100,000 shares Expires 2030-06-07 F2 · derivative.exercise_date: 2. 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024. Read SEC document |
| June 08, 2020 Filed Jun 12, 2020 21:44 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon stock | 450,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-20-006583 · section16.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 975,048 F1 · price: 1. These are restricted shares. 25% vests on June 7, 2021, with an additional 6.25% of the total shares vesting quarterly thereafter, subject to continued service through each vesting date until June 7, 2024 Read SEC document |
| December 19, 2019 Filed Dec 19, 2019 20:10 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Stock | 5,000 | $0.89 | $4,454.00 |
DisclosureSEC source: 0001654954-19-014096 · section16.xml · nonDerivative · entry 2 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,048 F1 · balance_after: Includes 453,475 restricted shares. Read SEC document |
| December 19, 2019 Filed Dec 19, 2019 20:10 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Stock | 50,000 | $0.89 | $44,370.00 |
DisclosureSEC source: 0001654954-19-014096 · section16.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,048 F1 · balance_after: Includes 453,475 restricted shares. Read SEC document |
| November 26, 2018 Filed Nov 28, 2018 02:40 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseWarrants (right to buy) · Derivative | 5,000 | $0.10 Strike: $72.00 | $500.00 |
DisclosureSEC source: 0001213900-18-016611 · ownership.xml · derivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2022-08-25 Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 23:49 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 445,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-014532 · ownership.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,048 F1 · price: These are restricted shares which vest on October 24, 2028, subject to earlier vesting in certain situations. F2 · balance_after: Aggregate amount indicated reflects 20-for-1 reverse split and includes additional 7,975 post-split restricted shares previously issued. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:39 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseWarrants · Derivative | 226,105 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001213900-18-002658 · f4030618joshdisbrow_aytubio.xml · derivative · entry 2 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,105 Underlying: Common Stock · 226,105 shares Expires 2023-03-06 F2 · price: Warrants were issued as part of units with the shares of common stock. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:39 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Stock | 226,105 | $0.45 | $101,747.25 |
DisclosureSEC source: 0001213900-18-002658 · f4030618joshdisbrow_aytubio.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490,949 F1 · balance_after: Includes 159,500 restricted shares. Read SEC document |
| November 07, 2017 Filed Nov 10, 2017 00:02 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-17-011711 · f4110717joshdisbrow_aytubio.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,844 F1 · shares: These are restricted shares that vest on November 7, 2027, subject to earlier vesting in certain situations. F1 · price: These are restricted shares that vest on November 7, 2027, subject to earlier vesting in certain situations. F2 · balance_after: Of these shares, 9,500 are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations. Read SEC document |
| August 15, 2017 Filed Aug 22, 2017 23:55 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantWarrant to Purchase Common Stock · Derivative | 2,500,000 | $0.18 Strike: $0.18 | $450,000.00 |
DisclosureSEC source: 0001638599-17-000784 · doc4_4897.xml · derivative · entry 2 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500,000 shares Expires 2022-08-15 Read SEC document |
| August 15, 2017 Filed Aug 22, 2017 23:55 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantCommon Stock | 1,666,667 | $0.15 | $250,000.05 |
DisclosureSEC source: 0001638599-17-000784 · doc4_4897.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,296,861 F1 · balance_after: Of these shares, 190,000 are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:18 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 60,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001638599-17-000289 · doc4_4621.xml · derivative · entry 8 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2026-07-07 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3 · derivative.exercise_date: 33.3% vests on July 7, 2017, 33.3% vests on July 7, 2018 and 33.4% on July 7, 2019, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:18 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 50,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001638599-17-000289 · doc4_4621.xml · derivative · entry 7 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-11-11 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2 · derivative.exercise_date: 33.3% vests on November 11, 2016, 33.3% vests on November 11, 2017 and 33.4% vests on November 11, 2018, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:18 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerEmployee Stock Option Grant · Derivative | 60,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001638599-17-000289 · doc4_4621.xml · derivative · entry 6 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2026-07-07 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3 · derivative.exercise_date: 33.3% vests on July 7, 2017, 33.3% vests on July 7, 2018 and 33.4% on July 7, 2019, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:18 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerEmployee Stock Option Grant · Derivative | 50,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001638599-17-000289 · doc4_4621.xml · derivative · entry 5 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-11-11 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2 · derivative.exercise_date: 33.3% vests on November 11, 2016, 33.3% vests on November 11, 2017 and 33.4% vests on November 11, 2018, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Aug 22, 2017 23:55 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 60,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001638599-17-000784 · doc4_4897.xml · derivative · entry 9 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2026-07-07 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3 · derivative.exercise_date: 33.3% vests on July 7, 2017, 33.3% vests on July 7, 2018 and 33.4% on July 7, 2019, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Aug 22, 2017 23:55 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 50,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001638599-17-000784 · doc4_4897.xml · derivative · entry 8 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-11-11 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2 · derivative.exercise_date: 33.3% vests on November 11, 2016, 33.3% vests on November 11, 2017 and 33.4% vests on November 11, 2018, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Aug 22, 2017 23:55 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerEmployee Stock Option Grant · Derivative | 60,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001638599-17-000784 · doc4_4897.xml · derivative · entry 7 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2026-07-07 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3 · derivative.exercise_date: 33.3% vests on July 7, 2017, 33.3% vests on July 7, 2018 and 33.4% on July 7, 2019, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Aug 22, 2017 23:55 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerEmployee Stock Option Grant · Derivative | 50,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001638599-17-000784 · doc4_4897.xml · derivative · entry 6 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-11-11 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2 · derivative.exercise_date: 33.3% vests on November 11, 2016, 33.3% vests on November 11, 2017 and 33.4% vests on November 11, 2018, subject to the Grantee's continued service as an employee on such dates. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 23:41 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Exercise / conversionWarran to Purchase Common Stock · Derivative | 20,834 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000229 · doc4_4570.xml · derivative · entry 3 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,834 shares Expires 2021-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 23:41 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Exercise / conversionWarrant to Purchase Common Stock · Derivative | 166,666 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001638599-17-000229 · doc4_4570.xml · derivative · entry 2 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 166,666 shares Expires 2021-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 23:41 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Exercise / conversionCommon Stock | 187,500 | $0.75 | $140,625.00 |
DisclosureSEC source: 0001638599-17-000229 · doc4_4570.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Of these shares, 190,000 are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 13:32 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseWarrant to Purchase Common Stock · Derivative | 28,924 | $0.07 Strike: $6.00 | $2,024.68 |
DisclosureSEC source: 0001638599-16-001707 · doc4_4409.xml · derivative · entry 2 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,924 Underlying: Common Stock · 28,924 shares Expires 2021-05-06 Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 20:57 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseWarrant to Purchase Common Stock · Derivative | 166,666 | Not disclosed Strike: $1.86 | Not disclosed |
DisclosureSEC source: 0001638599-16-001506 · doc4_4275.xml · derivative · entry 2 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,666 Underlying: Common Stock · 166,666 shares Expires 2021-11-02 F1 · price: The shares of stock and warrants were purchased at a purchase price per unit of $1.50. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 20:57 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseCommon Stock | 166,666 | $1.50 | $249,999.00 |
DisclosureSEC source: 0001638599-16-001506 · doc4_4275.xml · nonDerivative · entry 1 Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,694 F1 · price: The shares of stock and warrants were purchased at a purchase price per unit of $1.50. F2 · balance_after: Of these shares, 190,000 are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.